DRKS00012595招募中2 期
5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study - AIO-YMO/HEP-0316-IRIBI
Dekanat des Fachbereichs MedizinUniversitätsklinikum der Goethe-Universität Frankfurt0 个研究点目标入组 27 人开始时间: 2017年6月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Written informed consent granted prior to initiation of any study specific screening procedures
- •- Patients with histologically confirmed CCA or GB-CA not suitable for resection or metastatic
- •- Progressive disease after undergoing a systemic chemotherapy with a platin-derivate (Oxaliplatin, Cisplatin or Carboplatin) and Gemcitabine or progressive disease within 3 months after cessation of chemotherapy
- •- Age < 18 years
- •- Performance status ECOG 0-2
- •- Normal organ and bone marrow function defined as:
- •o Hematopoetic: absolute neutrophil count >1,500/mm3, platelet count >75,000/mm3, hemoglobin >9 g/dL
- •o INR = 1.5
- •o Hepatic: AST or ALT < 5 x ULN, bilirubin = 2 mg/dl
- •o Renal: serum creatinine < 1.5 x ULN
- •- Child Pugh stage A in patients with cirrhosis (Appendix 21.2)
- •- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the randomization
- •- Male or female patients of child-bearing potential must agree to use oral contraception, intrauterine device, bilateral tubal occlusion, vasectomised partner or avoidance of intercourse during the study and for 180 days after last investigational drug dose received
排除标准
- •- CCA or GB-CA amendable for surgical resection
- •- Prior radiation therapy, chemoradiation, transarterial chemoembolisation (TACE), Radiofrequency ablation (RFA) or selective intraarterial Radiotherapy (SIRT) within the last 3 months, radiation of symptomatic bone metastasis is allowed
- •- Concomitant photodynamic therapy or intraductal radiofrequency ablation within the last 8 weeks
- •- Child Pugh stage B or C (> 6 points) in patients with cirrhosis
- •- Massive, uncontrolled ascites
- •- Systemic anticancer chemotherapy other than Gemcitabin and a platin derivate (Cisplatin, Carboplatin or Oxaliplatin)
- •- Cardiac disease: congestive heart failure > class II NYHA
- •- Known uncontrolled brain metastasis
- •- History of bone marrow or organ allograft
- •- Active clinically serious infections > CTCAE grade 2 beside of chronic hepatitis C virus infection
- •- Major surgery within 4 weeks of first dose of study drug, port implantation is allowed
- •- Known or suspected allergies to 5-FU, folinic acid, irinotecan or other constituent materials or a known dihydropyrimidin-dehydrogenase deficiency
- •- Previous cancer that is distinct in primary site or histology from CCA or GB-CA except cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors or any cancer curatively treated 3 years prior to study entry
- •- Substance abuse, medical or psychological condition that may interfere with the patient´s participation in the study
- •- Participation in another clinical trial with any investigational study drug (whatever the use, curative, prophylactic or diagnostic intent) within 30 days prior to enrollment
- •- Pregnancy or breast feeding women
- •- Concomitant treatment with Brivudin, Sorivudin or their analogues or use of St. John's wort
- •- severe diarrhea
- •- inflammatory bowel disease and/or ileus
- •- - concomitant use of live attenuated vaccines during and 6 months after the end of chemotherapy
- •- Incapability to give valid informed consent (including patients who are dependent on the sponsor or the investigator)
研究者
相似试验
进行中（未招募）
1 期
5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 studybiliary tract cancer not amedable for curative resection with progressive disease after first-line chematherapy with gemcitabine and cisplatinEUCTR2015-004028-69-DEGoethe-Universität Frankfurt, PD Fabian Finkelmeier56
进行中（未招募）
1 期
al-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancerocally advanced or metastatic, non resectable, adenocarcinoma of the biliary tract including intrahepatic and extrahepatic bile ductMedDRA version: 21.1Level: LLTClassification code 10025734Term: Malignant neoplasm of biliary tract, part unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10028982Term: Neoplasm biliary tractSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002467-34-DEAIO-Studien-gGmbH92
招募中
2 期
Fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in non-resectable pancreatic cancer patients.Pancreatic cancerJPRN-UMIN000005808Yokohama City University Graduate School of Medicine60
Unknown
2 期
Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal CancerColorectal CancerNCT00075595GERCOR - Multidisciplinary Oncology Cooperative Group
进行中（未招募）
不适用
Combination of 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) with Concomitant or Concomitant and Maintenance Administration of Cetuximab (Erbitux®), in First-Line Treatment of Metastatic Colorectal Cancer. - Nordic VIIPatient with metastatic colorectal cancer.EUCTR2005-000117-34-ISThe Nordic Colorectal Cancer Biomodulation Group550